Full-Time
Site EHS Manager
Updated on 9/3/2026
IQVIA
10,001+ employees
Analytics, technology, and clinical research services.
No salary listed
Company Historically Provides H1B Sponsorship
Durham, NC, USA
In Person
Bachelor's
 Facilities Operations (1) |
|---|
Get referred to IQVIA
See people who can refer or advise you
- Bachelor's Degree in Technical or Safety related field
- Training or experience with biosafety in laboratory environments
- 3-5 years' relevant experience
- Working regulatory knowledge and experience interfacing with regulatory agencies
- Thorough knowledge of EHS legislation within the country
- Assess site EHS programs for prioritized risks and gaps.
- Assist Global Biosafety Officer and Vaccines Lab Director in evaluation of biosafety risk assessments and new protocols.
- Lead EHS governance elements and practices required to operate under ISO 14001 and ISO 45001 certification.
- Ensure corrective actions are implemented and documented in response to corporate, sponsor and site audits and reviews.
- Maintain site compliance calendar, ensure all recurring compliance actions are assigned and verify timely completion.
- Produce, implement, monitor, update and actively promote EH&S policies/procedures and safe systems of work at the site.
- Identify training needs and ensure the delivery of appropriate training to management, staff and site EH&S Representatives to ensure compliance with applicable legislation.
- Assist with the production, design, and implementation of EHS risk management.
- Manage the measurement and control of EHS performance.
- Coordinate EHS department representatives and lead monthly EHS committee meetings.
- Act as site Chemical Hygiene Officer
- Act as site Biosafety Officer and lead Institutional Biosafety Committee
- Maintain a current knowledge to ensure the site is compliant with applicable EHS regulations and best practices related to EHS.
- Work with site management to ensure appropriate corrective actions are taken on health, safety and environmental hazards or potential hazards.
- Assist investigation teams after recordable incidents to conduct RCAs and develop CAPAs.
- Ensure site regulatory compliance and reporting with corresponding agencies.
- Assist in ensuring compliance to SOPs in Q Squared Solutions EHS Management System or their more stringent regional equivalents..
- Provide coaching and support to the site sustainability champion to assist with Corporate Sustainability goals and implementation.
- Professional certification strongly preferred, e.g. Certified Safety Professional and/or Certified Industrial Hygienist (or equivalent certification in country or jurisdiction) or eligible for certification
- Thorough knowledge of EHS legislation within the country
- Good knowledge of the relevant local EHS regulations, international EHS management systems (e.g. ISO 14001 and OHSAS 18001 preferred)
- Good knowledge of corporate standards and policies
- Equivalent combination of education, training and experience
- Exceptional organization and analytical skills
- Excellent interpersonal skills that enable effective interaction/communication with management at many levels
- Effective leadership abilities
- Comfortable presenting and training in large and small groups (training/presentation, communication with site management)
- Excellent influencing skills
- Good technical writing skills
- Ability to establish and maintain effective working relationships with coworkers, managers, and clients
IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Its services combine deep clinical trial expertise with large datasets and analytics tools, delivered through the Connected Intelligence platform that links the healthcare ecosystem to generate insights while protecting patient privacy. The company differentiates itself by merging clinical research experience with expansive data resources and technology capabilities from its QuintilesIMS lineage, offering an integrated suite for faster research, development, and commercialization of medical treatments. IQVIA’s goal is to help pharmaceutical, biotech, and medical device companies, as well as researchers and governments, accelerate the development of new therapies and improve health outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1998
Get referred to IQVIA
See people who can refer or advise you
Simplify's Take
What believers are saying
- IQVIA raised 2026 guidance after Q2 revenue reached $4.368 billion and EBITDA beat targets.
- September 3, 2026 Predictive Clinical Development promises 33% faster startup and 50% faster cleaning.
- September 2026 refinancing uses $2 billion notes to retire 2026 debt and reduce maturity risk.
What critics are saying
- CNIL fined IQVIA Operations France €5 million on May 26, 2026, plus €10,000 daily delays.
- IQVIA sued former executives in April 2026, alleging a Syneos-led $180 million client raid.
- Repeated privacy breaches could cripple European data products and erode IQVIA's health-data moat.
What makes IQVIA unique
- IQVIA combines CRO execution with proprietary health data and commercial intelligence worldwide.
- IQVIA.ai, launched March 16, 2026, unifies agentic workflows across clinical, commercial, and real-world operations.
- Predictive Clinical Development leverages proprietary data, Prime and Partner sites, and regulated AI.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Flexible Work Hours
Paid Vacation
Wellness Program
401(k) Retirement Plan
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -1%IQVIA Holdings announced its subsidiary IQVIA Inc. priced an offering of $2 billion in senior notes due 2034. The notes will bear interest at 6.375% per annum, with semi-annual payments beginning 15 March 2027, and mature on 15 March 2034. Proceeds will be used to redeem the company's senior 5.000% notes due 2026, repay part of its outstanding revolving credit facility debt, and cover offering fees and expenses. The issuance is expected to close on or about 23 September 2026, subject to customary conditions. IQVIA is a global provider of clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare industries, employing approximately 94,000 people across over 100 countries.
HPM presenting at IQVIA Annual Controlled substances & State Regulatory Conference (sept. 16-18). September 4, 2026 Hyman, Phelps & McNamara, P.C.'s Karla Palmer and Andrew Hull will be speaking again at IQVIA's 28th Annual Controlled Substance & State Regulatory Conference in Scottsdale, AZ (Sept. 16-18). As part of a stacked agenda that runs the gamut on controlled substances issues, Ms. Palmer will speak on compliance considerations for compounders, and Mr. Hull will present on how registrants can mitigate risk and preserve reputation during a DEA investigation. Mr. Hull will also be presenting a course with retired DEA Chief Administrative Law Judge John J. Mulrooney, II, a partner at Belanger Rae & Mulrooney, on protecting your rights in DEA administrative actions. Join FDA Law Blog in Scottsdale for what promises to be another educational conference with key thought leaders and industry experts. Register here. Search FDA Law Blog. Subscribe. Never miss a post from FDA Law Blog
IQVIA's Predictive Clinical Development provides sponsors with significant efficiencies to get treatments to market faster. IQVIA introduces an AI-driven clinical development platform that reports sizable time savings from study startup through data cleaning and between trial phases. (Positive) See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google 09/03/2026 - 01:15 PM RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster. Traditional approaches in clinical development no longer keep pace with increasing trial complexity. IQVIA Predictive Clinical Development is built to eliminate them, accelerating every stage of the development lifecycle with measurable results: * 33% faster study startup * 1.7 times more patients recruited from our AI prioritized and Prime & Partner sites with 42% higher enrollment rates * 50% faster data cleaning * 45%+ reduced time between trial phases IQVIA Predictive Clinical Development pairs IQVIA's proprietary data, deep regulatory expertise and best-in-class Healthcare-grade AI(R) with premier technologies from Anthropic, Amazon Web Services (AWS), Databricks, Microsoft, NVIDIA, Palantir and Snowflake orchestrated to drive agentic workflows. "At a time when every moment matters for patients waiting on new therapies, IQVIA Predictive Clinical Development represents a fundamental shift," said Richard Staub, president of Research and Development Solutions at IQVIA. "We're helping customers make development faster, more predictable and of a higher quality - compressing timelines, accelerating decisions and speeding medicines to market." IQVIA Predictive Clinical Development is enabled by IQVIA's clinical AI capabilities: * Clinical Design & Planning Suite generates predictive insights to inform site selection, prioritizes sites including its Prime and Partner network and operationalizes the recruitment strategy to speed enrollment. * Push Button Start-Up is an integrated and streamlined delivery model that applies standardization, automation and AI-enabled processes to accelerate the time to starting patient enrollment. * Real-time Data Cleaning enables faster, more reliable, higher quality data to make confident decisions during and after a study. It brings clinical data together across multiple sources, drives greater efficiency and enables more rapid database locks. IQVIA is uniquely positioned to change the trajectory of clinical development ultimately closing the gap between scientific discovery to patient care. As IQVIA extends its leadership in AI, new components will continue to expand Predictive Clinical Development across the entire development lifecycle, helping customers move faster with confidence. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI(R), advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Kerri Joseph, IQVIA Investor Relations ([email protected]) +1.973.541.3558 Key terms. agentic workflows technical data cleaning technical database locks technical
IQVIA wins multiple industry awards for AI and Technology Innovation across life sciences and healthcare. August 27, 2026 at 16:15 PM EDT i This article is third-party content and does not represent the views of this site. Tamar Securities, LLC make no guarantees regarding its accuracy or completeness. IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution. Healthcare and life sciences organizations are under growing pressure to bring therapies to patients faster, make sense of rapidly expanding volumes of data and adopt AI they can trust. The recognized solutions help address these challenges by combining IQVIA's proprietary, expert-curated content and data with deep healthcare and life sciences domain knowledge and extensive experience operating in highly regulated environments where compliance, privacy and data governance are critical. This combination enables customers to turn insight into action with greater speed, precision and accuracy - identifying high-priority patients sooner, accelerating scientific literature reviews, enabling responsible data use at scale, improving regulatory efficiency and strengthening clinical trial supply performance. In addition to its recently announced AI Breakthrough Award for Best Predictive Modeling Solution of the Year, IQVIA has been recognized this year across multiple global technology awards including American Business Awards(R) Gold Stevie(R) for Technical Innovation of the Year - Healthcare Technology - Pharmaceuticals & Biotechnology; MedTech Breakthrough for Best Compliance Solution; American Business Awards(R) Silver Stevie(R) for Healthcare Technology Innovation; and another Silver Stevie(R) for Healthcare & Pharmaceuticals / Product. Granted by independent organizations that review thousands of submissions annually, the awards provide third-party validation of IQVIA's ability to deliver meaningful outcomes across R&D, data privacy, regulatory, trial operations and commercial domains. * American Business Awards(R) Gold Stevie(R)- Technical Innovation of the Year - Healthcare Technology - Pharmaceuticals & Biotechnology: Awarded to IQVIA Literature AI Platform, an agentic system built specifically for scientific literature review that demonstrated 100% recall in search, 93% or higher precision in document screening and more than a 90% reduction in screening workload compared with manual review. The IQVIA Literature AI Platform accelerates the process from search to synthesis while delivering rigorous, traceable outputs aligned with established quality standards. * MedTech Breakthrough - Best Compliance Solution: Awarded to IQVIA's Privacy Analytics Platform, which powers privacy-preserving data use. The technology is deployed within the NHS Federated Data Platform in England, which integrates health data from 55 million patients. The platform has contributed to measurable system impact, including enabling more than 110,000 additional procedures, reducing discharge delays for long-stay patients by 14.9% and supporting more than 90,000 patients in cancer care. * American Business Awards(R) Silver Stevie(R)- Healthcare Technology Innovation: Awarded to IQVIA SmartSolve(R) RIM, an AI-enabled Regulatory Information Management platform. It was recognized for helping accelerate global regulatory approvals, strengthen compliance and improve timely access to healthcare products. * American Business Awards(R) Silver Stevie(R)- Healthcare & Pharmaceuticals / Product: Awarded to the IQVIA Interactive Response Technology (IRT) Supply Automation Value Engine (SAVE) program, which uses real-time analytics and automation to optimize clinical trial drug supply. The program was recognized for reducing instances when trial sites ran out of needed medicines by 76% and cutting drug supply deliveries by 73%. * AI Breakthrough Award - Predictive Modeling Solution of the Year: Awarded to IQVIA's AI-enabled clinical decision support tool, developed in collaboration with Breakthrough T1D. The innovation identifies misdiagnosed and misclassified type 1 diabetes patients. It reduced screening burden by 99.5% - thereby requiring 200 times fewer patient assessments than before. The tool also delivered a ~127x improvement in identifying potential type 1 diabetes patients, with 28% of flagged patients confirmed or suspected to have type 1 diabetes compared with a 0.22% baseline. About IQVIA IQVIA (NYSE: IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI(R), advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Contacts. Kerri Joseph, IQVIA Investor Relations ([email protected]) +1.973.541.3558 Alissa Maupin, IQVIA Media Relations ([email protected]) +1.919.923.6785 Report this content If you believe this article contains misleading, harmful, or spam content, please let Tamar Securities, LLC know.
IQVIA Korea launches AI platform for smarter physician engagement. Home / Blog / IQVIA Korea launches AI platform for smarter physician engagement. August 26, 2026 Blog IQVIA Korea has launched MediLens, an AI-powered platform designed to help pharmaceutical and medical-device companies better understand healthcare professionals and sharpen physician engagement. The platform combines scientific and professional data with internal commercial information to generate insights into doctors' research interests, clinical expertise and activities. The move reflects AI's growing role in reshaping healthcare engagement strategies. Could MediLens set a new standard for data-driven physician engagement?